BOLD

Boundless Bio Inc. (BOLD) | Rumor.io

Boundless Bio

BOLD

Attention (50-day avg)0%

Attention rank (50-day avg)#3,255

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.15

Market capitalization59.4M

Earnings per share-2.8

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-58.2M

Social

What share of all stock conversation is about BOLD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jun 23

$BOLD has been added to a cash-dividend merger with Serapha Bio, with a concurrent $230 million private placement.
The company is expected to be acquired by Serapha Bio, with Boundless Bio shares potentially reaching $3.00 shortly.
Premarket volume for $BOLD has reached 13 million, with some traders shifting their focus from $HSCS to $BOLD.

Generated by AI

Sentiment

Of the messages about BOLD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.78% +39.83
Bearish	—	—	—	0.22% -39.83

Bullish· Jun 23

$BOLD has the potential to run on a squeeze or be acquired, which could drive its price higher.
The company has a merger agreement with Serapha Bio, which could lead to a significant increase in value.
$BOLD has shown strong momentum, with a 62.9% increase in value, and may continue to run hard, potentially surpassing $3.00.

Bearish· Jun 23

$BOLD is expected to fall to $1.40 or below $2, with some predicting a price drop to $1.5 or less.
The recent news about $BOLD's PDT ruling has destroyed momentum for the stock, and its high short interest suggests it may continue to decline.
The upcoming merger with Serapha may result in massive equity dilution, leaving legacy $BOLD shareholders with a heavily compressed upside and potentially dropping the stock price to less than $1.00.

Generated by AI

Topics

Of the messages about BOLD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	50%	43.6%
Controversies	50%	50%	50%	25.16%
Analysts	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	10.74%
Technical Analysis	0%	0%	0%	20.5%

Analysts· Dec 3

Analysts at Robert W. Baird upgraded BOLD to Neutral with a price target of $60.
HC Wainwright downgraded BOLD to Neutral with a price target of $60, citing the Astellas acquisition of Audentes.
BOLD's price target was lowered to $19.00 by Wells Fargo & Co, with an outperform rating remaining in place.

Announcements· Dec 4

Audentes Therapeutics (BOLD) was upgraded to "Neutral" by Citigroup, following a sell rating.
Astellas Pharma agreed to acquire Audentes Therapeutics (BOLD) for $3 billion, expanding its gene therapy capabilities.
Audentes Therapeutics (BOLD) was downgraded to "Market Perform" by Leerink Swann, following a previous upgrade to "Neutral" by Citigroup.

Generated by AI

Community

Of the messages about BOLD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	3.63%
Newcomers	100%	100%	100%	96.37%

News

Also Discussed

Investors talking about BOLD also mention

#	Name	Attention
1	Regenxbio Inc.RGNX	0%+0
2	Beam Therapeutics IncBEAM	0.02%+0.02
3	MeiraGTx Holdings plcMGTX	0%new
4	Prime Medicine, Inc.PRME	0%-0.01
5	ProQR Therapeutics N.V. Ordinary SharesPRQR	0%0
6	Passage Bio Inc.PASG	0%0
7	Qiagen N.V.QGEN	0%+0
8	ACHL - Achilles Therapeutics plc	——
9	Metagenomi Therapeutics, Inc.MGX	0%0
10	BioMarin Pharmaceutical IncBMRN	0%+0

Boundless Bio Inc.

Healthcare
Biotechnology

Boundless Bio Inc. is a clinical-stage oncology company focused on developing precision cancer therapies for tumors driven by oncogene amplification. Its work centers on extrachromosomal DNA (ecDNA), a biological mechanism that can fuel cancer growth, adaptation, and resistance to existing treatments. Using its proprietary Spyglass platform, Boundless Bio identifies ecDNA-related targets and designs ecDNA-directed therapeutic candidates intended to disrupt the pathways cancer cells use to survive. The company’s current pipeline includes oral small-molecule programs such as BBI-940 and other ecDNA-directed therapies being evaluated in clinical studies across hard-to-treat cancer types. Boundless Bio Inc. operates in the biotechnology sector and serves the broader oncology market with a research-driven approach aimed at addressing unmet needs in patients with oncogene-amplified cancers.

Website

Location

10955 Alexandria Way

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about BOLD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jun 23

$BOLD has been added to a cash-dividend merger with Serapha Bio, with a concurrent $230 million private placement.
The company is expected to be acquired by Serapha Bio, with Boundless Bio shares potentially reaching $3.00 shortly.
Premarket volume for $BOLD has reached 13 million, with some traders shifting their focus from $HSCS to $BOLD.

Generated by AI

Sentiment

Of the messages about BOLD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.78% +39.83
Bearish	—	—	—	0.22% -39.83

Bullish· Jun 23

$BOLD has the potential to run on a squeeze or be acquired, which could drive its price higher.
The company has a merger agreement with Serapha Bio, which could lead to a significant increase in value.
$BOLD has shown strong momentum, with a 62.9% increase in value, and may continue to run hard, potentially surpassing $3.00.

Bearish· Jun 23

$BOLD is expected to fall to $1.40 or below $2, with some predicting a price drop to $1.5 or less.
The recent news about $BOLD's PDT ruling has destroyed momentum for the stock, and its high short interest suggests it may continue to decline.
The upcoming merger with Serapha may result in massive equity dilution, leaving legacy $BOLD shareholders with a heavily compressed upside and potentially dropping the stock price to less than $1.00.

Generated by AI

Topics

Of the messages about BOLD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	50%	43.6%
Controversies	50%	50%	50%	25.16%
Analysts	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	10.74%
Technical Analysis	0%	0%	0%	20.5%

Analysts· Dec 3

Analysts at Robert W. Baird upgraded BOLD to Neutral with a price target of $60.
HC Wainwright downgraded BOLD to Neutral with a price target of $60, citing the Astellas acquisition of Audentes.
BOLD's price target was lowered to $19.00 by Wells Fargo & Co, with an outperform rating remaining in place.

Announcements· Dec 4

Audentes Therapeutics (BOLD) was upgraded to "Neutral" by Citigroup, following a sell rating.
Astellas Pharma agreed to acquire Audentes Therapeutics (BOLD) for $3 billion, expanding its gene therapy capabilities.
Audentes Therapeutics (BOLD) was downgraded to "Market Perform" by Leerink Swann, following a previous upgrade to "Neutral" by Citigroup.

Generated by AI

Community

Of the messages about BOLD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	3.63%
Newcomers	100%	100%	100%	96.37%

Boundless Bio

Social

Jun 23

Bullish· Jun 23

Bearish· Jun 23

Analysts· Dec 3

Announcements· Dec 4

Boundless Bio director Kevin Tang buys $11,865 in shares

Tang capital management, Kevin Tang buy $222k Boundless Bio stock

Kevin Tang’s Tang Capital buys $141,864 in Boundless Bio (BOLD)

Also Discussed

Boundless Bio Inc.

Company Information

Location

Boundless Bio director Kevin Tang buys $11,865 in shares

Tang capital management, Kevin Tang buy $222k Boundless Bio stock

Kevin Tang’s Tang Capital buys $141,864 in Boundless Bio (BOLD)

Also Discussed

Social

Jun 23

Bullish· Jun 23

Bearish· Jun 23

Analysts· Dec 3

Announcements· Dec 4